Belsomra, also known by its generic name suvorexant, is a medication used to treat insomnia [1]. It is a dual orexin receptor antagonist that works by blocking the action of orexin, a neurotransmitter that promotes wakefulness [2]. By inhibiting orexin signaling, Belsomra helps to reduce wakefulness and facilitate sleep [2].
How does Belsomra work?
Belsomra targets the orexin system in the brain, which is responsible for regulating the sleep-wake cycle. Orexin peptides (orexin-A and orexin-B) are produced in the hypothalamus and bind to orexin 1 (OX1) and orexin 2 (OX2) receptors, promoting wakefulness. Belsomra inhibits both OX1 and OX2 receptors, thereby suppressing the wake-promoting signals of orexin and aiding sleep initiation and maintenance [2][3].
What is Belsomra prescribed for?
Belsomra is prescribed for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1].
What are the potential side effects of Belsomra?
Common side effects of Belsomra can include somnolence, dizziness, and headache [1]. More serious side effects may include complex sleep behaviors such as sleep-driving, sleep-walking, or engaging in other activities while not fully awake and with no memory of the event [1]. Patients should not drive or engage in other dangerous activities until they know how Belsomra affects them [1].
When does Belsomra's patent expire?
The patent protection for Belsomra is a complex issue with multiple patents covering different aspects of the drug. According to DrugPatentWatch.com, Belsomra has faced several patent challenges and expirations for different patents [4]. For instance, a key patent related to the composition of matter for suvorexant (Belsomra) was set to expire around 2028, but other patents related to its use and manufacturing may have different timelines [4].
Are there alternatives to Belsomra for insomnia?
Yes, several alternatives exist for treating insomnia, including other prescription medications such as benzodiazepines (e.g., temazepam), non-benzodiazepine hypnotics (e.g., zolpidem, eszopiclone), and melatonin receptor agonists (e.g., ramelteon) [5]. Non-pharmacological treatments like Cognitive Behavioral Therapy for Insomnia (CBT-I) are also widely recommended as a first-line approach [6].
What is the difference between Belsomra and other sleep medications?
Unlike traditional hypnotics that directly sedate the central nervous system, Belsomra works by modulating the orexin system, which is involved in promoting wakefulness. This mechanism is thought to offer a different approach to managing insomnia, potentially with a different side effect profile for some individuals [2][5].
What is the clinical data supporting Belsomra's efficacy?
Clinical trials have demonstrated that Belsomra is effective in improving sleep onset latency and wake after sleep onset in adults with insomnia [3]. Studies have shown statistically significant improvements in these sleep parameters compared to placebo [3].
What are the risks associated with taking Belsomra?
Beyond the side effects mentioned, risks include the potential for daytime impairment, even when taken as prescribed [1]. Patients with liver or kidney problems, or a history of depression or suicidal thoughts, should use Belsomra with caution [1].
Who manufactures Belsomra?
Belsomra is manufactured by Merck & Co. [1].
Where can I find more information on Belsomra's patent status?
Detailed information on Belsomra's patent status, including expiration dates and any ongoing litigation, can be found on DrugPatentWatch.com [4].
Sources:
[1] https://www.belsomra.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790317/
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1204650
[4] https://drugpatentwatch.com/search/belsomra
[5] https://www.sleepfoundation.org/insomnia/treatment/sleep-medications
[6] https://www.hopkinsmedicine.org/health/wellness-and-prevention/insomnia-cognitive-behavioral-therapy-for-insomnia